Japan's Kaken Pharmaceutical and U.S.-based Brickell Biotech signed a license agreement for exclusive rights to develop, commercialize and manufacture the Miami-based firm's investigational compound BBI-4000 in Japan and other Asian countries for the treatment of hyperhidrosis.
Brickell Biotech will receive from Kaken an undisclosed upfront payment as well as milestone payments.
BBI-4000 is a new molecular entity that belongs to a class of drugs called "anticholinergics," that block a neurotransmitter called acetylcholine responsible for a range of bodily functions, including the activation of sweat glands.
Currently a placebo-controlled, double-blind Phase IIb study is underway in the U.S. among 180 patients with primary axillary hyperhidrosis.
- here's the release